statements comprise of the consolidated financial statements and the separate financial statements as compared with the financial statements for year 2016 ended December 31, 2016. The Company’s overall

31, 2018. Such financial statements comprise of the consolidated financial statements and the separate financial statements as compared with the financial statements for the first quarter of the year

1.29 8% Profit before income tax 38.10 27.85 Income tax expense 4.48 1.92 2.56 133% Profit for 6 months 33.62 25.93 7.69 30% 3.96% 3.67% Consolidated financial information 2 of 8 • Revenue increased by

statement for the year period ended December 31, 2018, details are as follows: The operating results of the consolidated financial statement for the year period ended December 31, 2018 The Consolidated

. DOD017/2562 May 8, 2019 Re: Management’s Discussion and Analysis (MD&A) of the Consolidated Financial Results for Quarter 1 of 2019 To: The President The Stock Exchange of Thailand DOD Biotech Public

2017 ended September 30, 2017. Such financial statements comprise of the consolidated financial statements and the separate financial statements as compared with the financial statements for the first

within 7 August 2020 and BSE will make payment for the purchase price and become a shareholder in RPV when all the conditions precedent according to the Share Sale and Purchase Agreement among ETP, BCPG

: President The Stock Exchange of Thailand CH. Karnchang Public Company Limited (“the Company”) and its subsidiaries would like to clarify the consolidated operating result and financial position for the year

7.01 40.54% Consolidated financial information The gross profit increased Baht 11.83 million or 20.58%; from Baht 57.49 million in quarter 1/2017 to Baht 69.31 million in quarter 1/2018, due to following

คำอธิบายและการวิเคราะห์ฐานะการเงินและผลการดำเนินงาน * Note Please find further information in the consolidated financial statements. 1 February 21st, 2020 Subject: Management Discussion & Analysis